From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Amplified target gene | Primer sequence | Amplified target gene | Primer sequence |
---|---|---|---|
HPV16 type mE6E7 primer | F: 5'-ATGCACCAAAAGAGAACT-3' | HPV18 type E6E7 primer | 5'-ATGGCGCGCTTTGAGGATCC-3' |
 | R: 5'-CCATCTGTTCTCAGAAACCA-3' |  | 5'-TGGTGTGCATCCCAGCAG-3' |
HPV18 type mE6E7 primer | F: 5'-ATGGCGCGCTTTGAGGATCC-3' | HPV58 type E6E7 primer | F: 5'-GTTCCAGGACGCAGAGGAG-3' |
 | R: 5'-TGGTGTGCATCCCAGCAG-3' |  | R: 5'-TTGCTGTGCACAGCTAGGTCA-3' |
HPV58 type mE6E7 primer | F: 5'-ATGTTCCAGGACGCAGAGGA-3' | Mouse β-actin primer | 5'-GAGACCTTCAACACCCCAGC-3' |
 | R: 5'-GCCCTAGCTGTGCACAGCAA-3' |  | 5'-CCACAGGATTCCATACCCAA-3' |
HPV16 type E6 primer | F: 5'-AATGTGTGTACTGCAAGCAAC-3' | Mouse GAPDH primer | 5'-AACTTTGGCATTGTGGAAGG -3' |
 | R: 5'-GACACAGTGGCTTTTGACAGT-3' |  | 5'-ACACATTGGGGGTAGGAACA-3' |
HPV16 type E7 primer | F: 5'-ATGGAGATACACCTACATTGC-3' | Â | Â |
 | R: 5'-CACAACCGAAGCGTAGAGTCA-3' |  |  |